Last reviewed · How we verify
NCT07220031
Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay
trial testing Activated Charcoal in Osmolality Disturbance in 8 participants. Not yet recruiting.
1 May 2026
Quick facts
| Lead sponsor | State University of New York - Upstate Medical University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 15 November 2025 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Activated Charcoal — full drug profile →
Conditions studied
- Osmolality Disturbance — all drugs for Osmolality Disturbance →
- Lab Interference — all drugs for Lab Interference →
Sponsor
State University of New York - Upstate Medical University
Who can join
18 and older, any sex, with Osmolality Disturbance or Lab Interference. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to determine whether a clinically relevant dose of activated charcoal raises the serum osmolality and osmolal gap in a population of healthy volunteers. Secondarily to determine whether the same dose creates a false positive result using an enzymatic assay. 1. Does a clinically relevant dose of commercially available activated charcoal raise the osmolal gap above the baseline of a healthy volunteer? 2. Does the same dose of charcoal cause a false positive enzymatic assay for ethylene glycol? Participants will be asked to consume a dose of activated charcoal and have serial blood draws for laboratory measurements.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07220031
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Activated Charcoal
Trials testing the same drug.
- NCT05471479 — Activated CHARcoal in Poisoned Patient - Pilot Trial · Phase 4 · recruiting
- NCT06595121 — Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension) · Phase 1 · completed
- NCT06219967 — Does a Soft Drink Mixture Improve Tolerance of Activated Charcoal in the Adult Poisoned Patient Without Affecting Effica · Phase 4 · completed
- NCT05540431 — Evaluation of Protective Effect of Activated Charcoal and Probiotic Against Progression of Chronic Kidney Disease · Phase 2, PHASE3 · unknown
Other recruiting trials for Osmolality Disturbance
Currently open trials in the same condition.
- NCT07267546 — Heart-Lung Machine: Impact of the Priming Solution on Acid-Base Balance, Electrolytes and Outcome on Patients Undergoing · NA · recruiting
Other State University of New York - Upstate Medical University trials
Trials by the same sponsor.
- NCT04736953 — Sirolimus Treatment Of Patients With SLE · Phase 2 · not yet recruiting
- NCT06370442 — Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult · Phase 3 · not yet recruiting
- NCT06045650 — Relationship Between Oxytocin Level, Trust, and Attachment in Individuals With Borderline Personality Disorder · not yet recruiting
- NCT05967455 — Homologous Re-infection With Dengue 1 or Dengue 3 · Phase 1 · completed
- NCT06112093 — Repetitive Transcranial Magnetic Stimulation for Post-concussion Headaches · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07220031 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by State University of New York - Upstate Medical University
- Last refreshed: 23 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07220031.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing